NCT01377233View on ClinicalTrials.gov

Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

February 29, 2012

Conditions
Schizophrenia
Interventions
DRUG

Zicronapine open-label lead-in 10 mg daily

Encapsulated tablet ,10 mg, once daily, open-label

DRUG

Zicronapine 10 mg daily

Encapsulated tablet, 10 mg, once daily, double-blind

DRUG

Zicronapine 20 mg once weekly

Encapsulated tablet, 20 mg, once weekly (on day 1 of each 7 day cycle), double-blind

DRUG

Zicronapine 30 mg once weekly

Encapsulated tablet, 30 mg, once weekly (on day 1 of each 7 day cycle), double-blind

DRUG

Zicronapine 45 mg once weekly

Encapsulated tablet, 45 mg, once weekly (on day 1 of each 7 day cycle), double-blind

Trial Locations (4)

20850

US001, Rockville

91950

US003, National City

92102

US004, San Diego

92845

US002, Garden Grove

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT01377233 - Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter